Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 15/20 | 1.00 |
| ▸ | TDP2 | O95551 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18326676 | 0.94 | TDP1 (0.90) | TDP1TDP2MAPK1HSD17B10LMNA | |
| SCHEMBL18326691 | 0.93 | TDP1 (0.86) | TDP1TDP2MAPK1HSD17B10LMNA | |
| SCHEMBL21173507 | 0.90 | TDP1 (0.82) | TDP1TDP2MAPK1HSD17B10LMNA | |
| SCHEMBL17192726 | 0.90 | TDP1 (0.82) | TDP1TDP2MAPK1HSD17B10LMNA | |
| SCHEMBL18319822 | 0.89 | TDP1 (0.80) | TDP1TDP2MAPK1HSD17B10LMNA | |
| Indotecan SCHEMBL7712572 | 0.87 | TDP1 (0.87) | TDP1TDP2MAPK1HSD17B10LMNA | |
| Indotecan SCHEMBL29409466 | 0.87 | TDP1 (0.87) | TDP1TDP2MAPK1HSD17B10LMNA | |
| SCHEMBL18326700 | 0.86 | TDP1 (0.76) | TDP1TDP2 | |
| Bromide SCHEMBL18320288 | 0.86 | TDP1 (0.75) | TDP1TDP2 | |
| SCHEMBL18329662 | 0.84 | TDP1 (0.72) | TDP1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367685-A1 | DUPA-INDENOISOQUINOLINE CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| WO-2015069766-A1 | DUPA-INDENOISOQUINOLINE CONJUGATES | PURDUE RESEARCH FOUNDATION (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367685-A1 | DUPA-INDENOISOQUINOLINE CONJUGATES | PDS5B, KLK3, PDS5A | TDP1 483/4885TDP2 311/4885MAPK1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.